Vor Biopharma (VOR) Could Be 51% Undervalued After Fresh Phase 3 gMG Data

Vor Biopharma (VOR) is back in focus after new post hoc data from a Phase 3 gMG trial with partner RemeGen showed many patients achieved, and often maintained, minimal symptom expression on telitacicept.

Investors have reacted positively to the fresh gMG data, with Vor Biopharma’s share price up 4.09% over the past day and 3.47% across the week. However, the 30 day share price return is down 15.72% and the 1 year total shareholder return has fallen 47.98%. This leaves year to date share price momentum of 63.92% looking strong, but still set against heavy longer term losses.

Scan beyond Vor Biopharma and see how other potential turnaround stories with fresh clinical data or underappreciated momentum stack up in our hand picked 19 high quality undiscovered gems

Vor Biopharma now trades with a sharp year to date rebound, yet remains weighed down by heavy multi year losses. Does that mix argue for stepping in after this data pop, or for waiting for a cleaner reset on price?

Most Popular Narrative: 51% Undervalued

The most followed valuation storyline pegs Vor Biopharma’s fair value at $39 per share, compared with the last close at $19.08, which sets up a wide gap that only closes if the late stage autoimmune pipeline delivers as outlined.

A strong cash position of about US$491.5m that is projected to fund operations into early 2029 reduces near term financing needs, which can limit potential equity dilution and support net income and per share earnings outcomes if late stage programs reach commercialization.

See why 1 investors see Vor Biopharma as 51% undervalued.

Result: Fair Value of $39 (UNDERVALUED)

Still, the Vor Biopharma story can change quickly if global Phase 3 data disappoints or if telitacicept struggles to stand out against entrenched autoimmune competitors.

Find out about the key risks to this Vor Biopharma narrative.

Next Steps

Mixed signals across Vor Biopharma’s story can be useful, but only if you pressure test them yourself and move before the next narrative shift. Take a few minutes to weigh up the 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Vor Biopharma?

If you stop at Vor Biopharma, you risk missing other opportunities that fit your style, match your risk comfort, and line up better with your watchlist priorities.

• Target resilient balance sheets by scanning a list of solid balance sheet and fundamentals (25 results) that filters for companies with the financial strength to handle rougher patches.
• Hunt for mispriced quality by checking the 31 high quality undervalued stocks that highlights businesses trading below what their fundamentals may suggest.
• Prioritise capital preservation by reviewing a 31 resilient stocks with low risk scores focused on stocks with lower risk scores that might suit more cautious portfolios.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com